본문 바로가기
KERD
논문KCI 등재

The Relationship between 10 Years Risk of Cardiovascular Disease and Schizophrenia Symptoms: Preliminary Results

Esin Evren Kilicaslan|Merve Karakilic|Almila Erol
대한신경정신의학회 (Korean Neuropsychiatric Association)|2019.12|PSYCHIATRY INVESTIGATION|제16권 제12호|pp. 933-939|DOI https://doi.org/10.30773/pi.2019.0063

6

조회

0

다운로드

0

인용

0

참고문헌

키워드

SchizophreniaCardiovascular riskFramingham risk scoreSchizophrenia symptomsAntipsychotic treatment.
주제분류정신과학

초록

Objective Previous research shows that patients with schizophrenia have increased cardiovascular disease risk than general population. Increased cardiovascular risk in schizophrenia patients have been associated with many reasons such as antipsychotic drugs, genetic predisposition, andlifestyle. In this study, we aimed to investigate the relationship between the risk of heart disease and schizophrenia symptomatology. Methods The 10-year cardiovascular risk was assessed by the Framingham Risk Score (FRS) in 103 patients with schizophrenia and in 39 healthy controls. Sociodemographic characteristics, age at schizophrenia onset, duration of illness, number of hospitalizations, the course of the disease and antipsychotic medications were recorded. Patients’ symptoms were evaluated via The Scale for the Assessment of Negative Symptoms (SANS), The Scale for the Assessment of Positive Symptoms (SAPS), and Calgary Depression Scale for Schizophrenia (CDSS). Results Ten-year cardiovascular risk was 5.16% inpatients with schizophrenia, and 3.02% in control group (p=0.030). No significant correlation was found between FRS scores, SANS, SAPS, and CDSS scores. However, FRS scores were significantly correlated with age, number of hospitalizations and duration of disease (r=0.300, 0.261, 0.252, respectively). Moreover FRS scores were higher (p=0.008) and highdensity lipoprotein (HDL) levels were lower (p=0.048) in patients using multiple antipsychotics. Conclusion Our findings suggest a relationship between the risk of cardiovascular disease and the duration and overall severity of schizophrenia and also highlights the role of antipsychotics in this relationship.

Abstract

Objective Previous research shows that patients with schizophrenia have increased cardiovascular disease risk than general population. Increased cardiovascular risk in schizophrenia patients have been associated with many reasons such as antipsychotic drugs, genetic predisposition, andlifestyle. In this study, we aimed to investigate the relationship between the risk of heart disease and schizophrenia symptomatology. Methods The 10-year cardiovascular risk was assessed by the Framingham Risk Score (FRS) in 103 patients with schizophrenia and in 39 healthy controls. Sociodemographic characteristics, age at schizophrenia onset, duration of illness, number of hospitalizations, the course of the disease and antipsychotic medications were recorded. Patients’ symptoms were evaluated via The Scale for the Assessment of Negative Symptoms (SANS), The Scale for the Assessment of Positive Symptoms (SAPS), and Calgary Depression Scale for Schizophrenia (CDSS). Results Ten-year cardiovascular risk was 5.16% inpatients with schizophrenia, and 3.02% in control group (p=0.030). No significant correlation was found between FRS scores, SANS, SAPS, and CDSS scores. However, FRS scores were significantly correlated with age, number of hospitalizations and duration of disease (r=0.300, 0.261, 0.252, respectively). Moreover FRS scores were higher (p=0.008) and highdensity lipoprotein (HDL) levels were lower (p=0.048) in patients using multiple antipsychotics. Conclusion Our findings suggest a relationship between the risk of cardiovascular disease and the duration and overall severity of schizophrenia and also highlights the role of antipsychotics in this relationship.

참고문헌 (70)

  1. Lawrence D, "The epidemiology of excess mortality in peoplewith mental illness", Can J Psychiatry, 55, pp.752~760 (2010)
  2. Allebeck P, "Schizophrenia : a life-shortening disease", Schizophr Bull, 15, pp.81~89 (1989)
  3. Allison DB, "The distribution of bodymass index among individuals with and without schizophrenia", J Clin Psychiatry, 60, pp.215~220 (1999)
  4. Coodin S, "Body mass index in persons with schizophrenia", Can J Psychiatry, 46, pp.549~555 (2001)
  5. Goldman LS, "Medical illness in patients with schizophrenia", J Clin Psychiatry, 60, pp.10~15 (1999)
  6. Sasaki J, "Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines", Atherosclerosis, 51, pp.163~169 (1984)
  7. Lindenmayer JP, "Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics", Am J Psychiatry, 160, pp.290~296 (2003)
  8. Ryan MC, "Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia", Am J Psychiatry, 160, pp.284~289 (2003)
  9. Jeste DV, "Medical comorbidity in schizophrenia", Schizophr Bull, 22, pp.413~430 (1996)
  10. Vieweg V, "Medical disorders in the schizophrenic patient", Int J Psychiatry Med, 25, pp.137~172 (1995)
  11. Folsom DP, "Medical comorbidity and receipt of medical care by older homeless people with schizophrenia or depression", Psychiatr Serv, 53, pp.1456~1460 (2002)
  12. Wilson PW, "Prediction of coronary heart disease using risk factor categories", Circulation, 97, pp.1837~1847 (1998)
  13. Bitton A, "The Framingham Heart Study’s impact on global risk assessment", Prog Cardiovasc Dis, 53, pp.68~78 (2010)
  14. Suka M, "Application of the updated Framingham risk score to Japanese men", Hypertens Res, 24, pp.685~689 (2001)
  15. Marrugat J, "Coronaryrisk estimation in Spain using a calibrated Framingham function", Rev Esp Cardiol, 56, pp.253~261 (2003)
  16. Liu J, "Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study", JAMA, 291, pp.2591~2599 (2004)
  17. Eichler K, "Prediction of first coronary events with the Framingham score : a systematic review", Am Heart J, 153, pp.722~731 (2007)
  18. Lee J, "The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study. Clin Endocrinol (Oxf) 2008;69:225–230", Clin Endocrinol(Oxf), 69, pp.225~230 (2008)
  19. Goff DC, "A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls", Schizophr Res, 80, pp.45~53 (2005)
  20. Osborn DPJ, "Cardiovascular risk prediction models for people with severemental illness : results from the prediction and management of cardiovascular risk in people with severe mental illnesses(PRIMROSE)research program", JAMA Psychiatry, 72, pp.143~151 (2015)
  21. Cohn T, "Characterizing coronaryheart disease risk in chronic schizophrenia : high prevalence of the metabolic syndrome", Can J Psychiatry, 49, pp.753~760 (2004)
  22. Bobes J, "Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders : an analysis of theimpact of smoking tobacco in the CLAMORS schizophrenia cohort", Schizophr Res, 119, pp.101~109 (2010)
  23. Yazici MK, "The prevalence and clinical correlates of metabolic syndromein patients with schizophrenia : findings from a cohort in Turkey", Eur Arch Psychiatry Clin Neurosci, 261, pp.69~78 (2011)
  24. Jin H, "Increased Framingham 10-year risk of coronary heart diseasein middleaged and older patients with psychotic symptoms", Schizophr Res, 125, pp.295~299 (2011)
  25. Ratliff JC, "Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular riskand vascular ages than obese individuals without severe mental illness", Psychosomatics, 54, pp.67~73 (2013)
  26. Arango C, "A comparison of schizophrenia outpatients treated with antipsychotics with and withoutmetabolic syndrome : findings from the CLAMORS study", Schizophr Res, 104, pp.1~12 (2008)
  27. Barak Y, "Assessing cardiovascular risks of olanzapine treatment : a 6-month study versus haloperidol in schizophrenia patients", Int Clin Psychopharmacol, 20, pp.315~317 (2005)
  28. Barnett AH, "UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronaryheart disease risk projections (STAR study)", Eur Arch Psychiatry Clin Neurosci, 259, pp.239~247 (2009)
  29. Correll CU, "Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generationantipsychotic drugs", J Clin Psychiatry, 67, pp.575~583 (2006)
  30. Del Valle MC, "Change in Framingham risk score in patients with schizophrenia : a post hoc analysis of arandomized, double-blind, 6-week trial of ziprasidone and olanzapine", Prim Care Companion J Clin Psychiatry, 8, pp.329~333 (2006)
  31. McCreadie RG, "Diet, smoking and cardiovascular risk in people with schizophrenia : descriptive study", Br J Psychiatry, 183, pp.534~539 (2003)
  32. Laursen TM, "Life expectancy and cardiovascular mortality in persons with schizophrenia", Curr Opin Psychiatry, 25, pp.83~88 (2012)
  33. Arangoa C, "Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia : Findings from the CLAMORS study", Eur Neuropsychopharmacol, 21, pp.867~875 (2011)
  34. Andreasen NC, "Methods for assessing positive and negative symptoms", Mod Probl Pharmacopsychiatry, 24, pp.73~88 (1990)
  35. Addington D, "Reliability and validity of a depression rating scale for schizophrenics", Schizophr Res, 6, pp.201~208 (1992)
  36. Erkoç Ş, "Reliability and validity of the Turkish version of Scale for the Assessment of Positive Symptoms", Düşünen Adam, 4, pp.20~24 (1991)
  37. Erkoç Ş, "Reliability and validity of the Turkish version of Scale for the Assessment of Negative Symptoms", Düşünen Adam, 4, pp.16~19 (1991)
  38. Aydemir Ö, "Reliability and validity of the Turkish version of Scale for the Assessment of Calgary Depression Scale for Schizophrenia", Arch Neuropsychiatry, 37, pp.210~213 (2000)
  39. Tay YH, "Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia", Schizophr Res, 147, pp.187~192 (2013)
  40. Zhao S, "10-year CVD risk in Han Chinese mainland patients with schizophrenia", Psychiatry Res, 264, pp.322~326 (2018)
  41. Emul M, "Etiology of cardiovascular disease in patients with schizophrenia : current perspectives", Neuropsychiatr Dis Treat, 11, pp.2493~2503 (2015)
  42. Raphael TP, "Blood sugar studies in dementia praecox and manic-depressive insanity", Arch Neurol Psychiatry, 5, pp.687~709 (1921)
  43. Ryan MC, "Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia", Am J Psychiatry, 160, pp.284~289 (2003)
  44. Hansen T, "At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia", Biol Psychiatry, 70, pp.59~63 (2011)
  45. Le Hellard S, "Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?", Mol Psychiatry, 14, pp.308~317 (2009)
  46. Bai YM, "Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics", Schizophr Res, 125, pp.179~186 (2011)
  47. Burghardt K, "Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia", J Psychopharmacol, 28, pp.349~356 (2014)
  48. Perkins DO, "microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder", Genome Biol, 8, pp.R27~ (2007)
  49. de Bartolomeis A, "MicroRNAs in schizophrenia: implications for synaptic plasticity and dopamineglutamate interaction at the postsynaptic density. New avenues for antipsychotic treatment under a theranostic perspective", Mol Neurobiol, 52, pp.1771~1790 (2015)
  50. Gardiner E, "Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells", Mol Psychiatry, 17, pp.827~840 (2012)
  51. Santarelli DM, "Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine", Psychopharmacology(Berl), 227, pp.67~78 (2013)
  52. De Leon J, "A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviours", Schizophr Res, 76, pp.135~157 (2005)
  53. Chapman S, "Citation bias in reportedsmoking prevalence in people with schizophrenia", Aus N Z J Psychiatry, 43, pp.277~282 (2009)
  54. de Leon J, "Smoking and vulnerability for schizophrenia", Schizophr Bull, 22, pp.405~409 (2006)
  55. Poirier MF, "Prevalence of smoking in psychiatric patients", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.529~537 (2002)
  56. de Leon J, "Variables associated with alcohol, drug, and daily smoking cessation inpatients with severe mental illnesses", J Clin Psychiatry, 66, pp.1447~1455 (2005)
  57. Barr AM, "Selfreported motivation to smoke in schizophrenia is related to antipsychoticdrug treatment", Schizophr Res, 100, pp.252~260 (2008)
  58. Barnett AH, "Missing metabolic and cardiovascular risk in schizophrenia : diabetes, obesity and dyslipidaemia", J Psychopharmacol, 21, pp.357~373 (2007)
  59. Von Hausswolff-JuhlinY, "Schizophreniaand physical health problems", Acta Psychiatr Scand Suppl, 438, pp.15~21 (2009)
  60. Correll CU, "Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder", World Psychiatry, 14, pp.119~136 (2015)
  61. Daumit GL, "A behavioral weight-loss intervention in persons with serious mental illness", N Engl J Med, 368, pp.1594~1602 (2013)
  62. Ganguly R, "Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000", J Clin Psychiatry, 65, pp.1~12 (2004)
  63. Weinmann S, "Influence of antipsychotics on mortality in schizophrenia : systematic review", Schizophr Res, 113, pp.1~11 (2009)
  64. Baxter A, "Reducing excess mortality due to chronic disease in people with severe mental illness : meta-review of health interventions", Br J Psychiatry, 208, pp.322~329 (2016)
  65. Bressington D, "Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders : a cross-sectional study", BMC Psychiatry, 16, pp.411~ (2016)
  66. Huang KL, "Myocardial infarction risk and antipsychotics use revisited : a meta-analysis of 10 observational studies", J Psychopharmacol, 31, pp.1544~1555 (2017)
  67. Wildi H, "Clinical outcomes of depot and well being clinic. Results of physical health care checks", Psychiatr Danub, 25(Suppl 2), pp.S174~S177 (2011)
  68. Sanchez-Martinez V, "Metabolic syndrome and cardiovascular risk in people treated with long-acting injectable antipsychotics", Endocr Metab Immune Disord Drug Targets, 18, pp.379~387 (2018)
  69. Emsley R, "Oral versus injectable antipsychotic treatment in early psychosis : post hoc comparison of two studies", Clin Ther, 30, pp.2378~2386 (2008)
  70. Rosa F, "Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable", Clin Drug Investig, 32, pp.267~279 (2012)

관련 논문AI추천

Arterial Stiffness in Patients Taking Second-generation AntipsychoticsEbru Fındıklı, Hüseyin Avni Fındıklı, Mehmet Akif Camkurt, Mehmet Fatih Karaaslan, Merve Coşgun Şahin, Mustafa Gökçe, Selçuk Kardas, Vedat Nacitarhan대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2016 · 제14권 제4호Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics김세현, 이남영, Han Young You, In Won Chung, Seong Hoon Jeong, Tak Youn, Ung Gu Kang, Yong Min Ahn, Yong Sik Kim대한신경정신의학회 · PSYCHIATRY INVESTIGATION2018 · 제15권 제6호Elevated Monocyte to High-density Lipoprotein Ratios as an Inflammation Markers for Schizophrenia PatientsDuygu Ayar, Mehmet Akif Karaman, Musa Sahpolat, Mustafa Ari대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2021 · 제19권 제1호성인 조현병 환자의 심혈관질환 동반에 따른 입원 위험 및 질병 비용: 후향적 단면연구강혜영, 조윤재한국보건의료기술평가학회 · 보건의료기술평가2023 · 제11권 제1호The Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics강시현, 고유경, 소민아, 이종일대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2013 · 제11권 제2호Serum Levels of High Sensitivity C-reactive Protein in Drug-naïve First-episode Psychosis and Acute Exacerbation of SchizophreniaAbdullah Akgün, Abdullah Bolu, Ali Coşkun, Beyazıt Garip, Cemil Çelik, Mehmet Sinan Aydın, Özcan Uzun, Taner Öznur대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2019 · 제17권 제2호

이 간행물의 다른 논문 (11건)

How to Develop Psychiatry Investigation into a World Class JournalHeon-Jeong Leepp. 875-876Neuropsychiatric Symptoms of Multiple Sclerosis: State of the ArtCeleste Silveira, Renato Guedes, Diana Maia, Rosário Curral, Rui Coelhopp. 877-888Cognitive Decline in Korean Patients with Neurocognitive Disorder due to Traumatic Brain Injury: A Control for Premorbid IntelligenceSeung-Ho Jang, Sang-Yeol Lee, Kyu-Sic Hwang, Hye-Jin Lee, Min-Jung Sohpp. 889-895The Effect of Workplace Violence on Depressive Symptoms and the Mediating Role of Psychological Capital in Chinese Township General Practitioners and Nurses: A Cross-Sectional StudyLie Wang, Chi Tong, Chunying Cui, Yifei Lipp. 896-903The Psychometric Properties of the Patient Health Questionnaire-9 in a Sample of Korean University StudentsBoram Lee, Yang Eun Kimpp. 904-910
원문 보기